Looking back on the past year, it’s been an exceptional period marked by hard work, scientific rigor, and strong collaboration, even as the biotech ecosystem continued to face significant financial and strategic headwinds.
Our priority remained clear: supporting our customers with the critical ADME data they need to make confident, timely decisions. As the industry shifted further toward later-stage assets, we worked flexibly and pragmatically with our partners—navigating constraints while never compromising on quality or scientific integrity.
Customer feedback on our services remained outstanding, with heart-warming feedback received from both long-standing and new partners. Thank You! Clients especially valued our fast, transparent communication, direct access to study-responsible scientists, and our ability to design bespoke, compound-specific studies alongside robust, standardized screening workflows, all delivered with high technical quality. We stand for this reputation every day.
Much of our work, across both early-stage ADME screening and tailored late-stage mechanistic assays, is carried out in advanced in vitro systems such as hepatocyte-based models, recombinant enzyme systems, and transporter assays. These approaches align well with the FDA’s emphasis on Novel Alternative Methods (NAMs), helping reduce reliance on animal studies while maintaining confidence in decision-making. Reflecting this focus, we recently launched new in vitro screening assays to identify mechanisms and risks of drug-induced liver injury (DILI). Where needed, we continue to provide high-quality in vivo pharmacokinetic and mass balance studies as part of an integrated ADME strategy.
The ADME field continues to evolve rapidly, driven by emerging therapeutic modalities and advances in research technologies. Over the past year, we supported customer programs across a wide range of modalities—including PROTACs, siRNA, antisense oligonucleotides, pro-drugs, and antibody–drug conjugates—demonstrating our flexibility, analytical depth, and long-standing expertise in tailored assay systems.
Among our key achievements were the consistent delivery of eCTD-compatible reports, further automation of assays through advanced liquid handling, and continued investment in new technologies, assay optimization, and instrumentation. We also successfully completed multiple customer and regulatory audits, strengthened our global IT security standards, and continued to enhance our quality systems. Across Symeres, we made strong progress on our ESG commitments, including Science Based Targets initiative (SBTi) approval of our carbon-reduction goals and the publication of a transparent SME sustainability report.
A real highlight of the year was the close collaboration across Symeres’ multidisciplinary drug discovery and development teams. By delivering complex programs as fully integrated efforts, we enabled our clients to benefit from seamless, end-to-end solutions. We were also delighted to welcome new colleagues from Double Green Pharma, whose complementary regulatory expertise in nonclinical and clinical drug development further strengthens our offering.
Our dedication to excellence is non-negotiable, and to develop further we will look at further expansion of automation and software-enabled workflows. Our customers can continue to rely on Admescope team and the whole Symeres scientific community, for open, nimble and expert innovative insights that power smarter drug discovery and development decisions.
Written by Outi Kontkanen
